These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 17642005)
1. BIO 2007 Annual International Convention. Investigational drug activities in Asia: focus on China, Taiwan and Japan. Tear S IDrugs; 2007 Jul; 10(7):427-9. PubMed ID: 17642005 [No Abstract] [Full Text] [Related]
2. BIO 2007 Annual International Convention. Highlights from the exhibition hall. Tear S IDrugs; 2007 Jul; 10(7):430-2. PubMed ID: 17642006 [No Abstract] [Full Text] [Related]
3. China offers alternative gateway for experimental drugs. Jia H; Kling J Nat Biotechnol; 2006 Feb; 24(2):117-8. PubMed ID: 16465139 [No Abstract] [Full Text] [Related]
4. Japan Biotech Forum: London 2010. Al-Shamahi A IDrugs; 2010 Nov; 13(11):756-8. PubMed ID: 21046519 [TBL] [Abstract][Full Text] [Related]
5. Japan-China merger puts growth in East Asia first. Sipp D Nat Biotechnol; 2005 Aug; 23(8):907. PubMed ID: 16082348 [No Abstract] [Full Text] [Related]
6. Bangalore India Bio 2010. Thammanabhatla P; Pailla M IDrugs; 2010 Aug; 13(8):527-9. PubMed ID: 20721821 [TBL] [Abstract][Full Text] [Related]
7. Japanese universal health care faces a crisis in cancer treatment. Fujiwara Y; Yonemori K; Shibata T; Okita N; Ushirozawa N Lancet Oncol; 2015 Mar; 16(3):251-2. PubMed ID: 25752548 [No Abstract] [Full Text] [Related]
8. BIO 2006 Annual International Convention. Innovations in biotech in China and Italy. Tear S; Zarkowska T IDrugs; 2006 Jun; 9(6):386-9. PubMed ID: 16752303 [No Abstract] [Full Text] [Related]
9. Biotechnology Industry Organization-- BIO 2006: Annual International Convention; 9-12 April, 2006; Chicago, Illinois, USA. Bardsley-Elliot A BioDrugs; 2006; 20(3):181-90. PubMed ID: 16724866 [No Abstract] [Full Text] [Related]
10. Market watch: Upcoming market catalysts in Q3 2016. Ranj T Nat Rev Drug Discov; 2016 Jul; 15(7):449. PubMed ID: 27282354 [No Abstract] [Full Text] [Related]
12. [Rational introduction to new drugs requires both a health care and a community perspective]. Gustafsson LL; Wettermark B; Kalin M; Korkmaz S; Persson ME; Almkvist H; Hjemdahl P; Julander M; Kristianson K; Ringertz B; Bergendahl GT; Wiking N Lakartidningen; 2009 Jan 7-13; 106(1-2):52. PubMed ID: 19235325 [No Abstract] [Full Text] [Related]
14. Pharmaceutical manufacturers seek OIG comfort. Becker S Health Care Law Mon; 2002 Aug; ():3-6. PubMed ID: 12420396 [No Abstract] [Full Text] [Related]
15. Japan works to shorten "drug lag," boost trials of new drugs. Sinha G J Natl Cancer Inst; 2010 Feb; 102(3):148-51. PubMed ID: 20107160 [No Abstract] [Full Text] [Related]
16. Drug development in the Pacific Rim. Wong J Clin Adv Hematol Oncol; 2006 Sep; 4(9):670-2. PubMed ID: 17099623 [No Abstract] [Full Text] [Related]
17. [Structured introduction of new drug therapies: valuable initiative--transparency required]. Lundkvist J; Henriksson F Lakartidningen; 2009 Jan 7-13; 106(1-2):51. PubMed ID: 19235324 [No Abstract] [Full Text] [Related]
18. The year's new drugs. Graul AI; Prous JR Drug News Perspect; 2005; 18(1):21-36. PubMed ID: 15753973 [TBL] [Abstract][Full Text] [Related]
19. The era of cancer discovery. Cantley LC; Baselga J Cancer Discov; 2011 Jun; 1(1):1. PubMed ID: 22586302 [No Abstract] [Full Text] [Related]
20. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform. Rossen BR Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]